Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease

• Published in: The oncologist (Dayton, Ohio) Vol. 25; no. 4; pp. e709 - e715
• Main Authors: Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.04.2020
• Subjects: Acute lymphoblastic leukemia; CHMP; COMP; EMA; Hematopoietic stem cell transplant; Minimal residual disease; PRAC; COMP; Hematopoietic stem cell transplant; PRAC; Acute lymphoblastic leukemia; CHMP; EMA; Minimal residual disease

On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab was authorized to...